Evidence map›Paper›PMID 39738220›Full record

ArticleScientific reports2024

Bioinformatics analysis of miRNAs germacrone protection on diabetic nephropathy.

Binqi Wang, Wenfang He, Zhixuan Xie, Jinshi Zhang, Yan Ren, Qiang He, Juan Jin

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Binqi Wang *The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310000, People's Republic of China.
Wenfang He *Urology & Nephrology Center, Department of Nephrology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, People's Republic of China.
Zhixuan Xie *Department of Nephrology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, People's Republic of China.
Jinshi ZhangThe First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310000, People's Republic of China.
Yan RenUrology & Nephrology Center, Department of Nephrology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, People's Republic of China.
Qiang HeDepartment of Nephrology, the First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, 310000, People's Republic of China. qianghe1973@126.com.
Juan JinDepartment of Nephrology, the First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, 310000, People's Republic of China. lang_018@163.com.

Funding

the Construction of Key Projects by Zhejiang Provincial Ministry No.WKJ-ZJ-2017the Fundamental scientific research project of Hangzhou Medical College KYQN2023009the Huadong Medicine Joint Funds of the Zhejiang Provincial Natural Science Foundation of China No. LHDMZ22H050001the Key Project of Basic Scientific Research Operating Funds of Hangzhou Medical College KYZD202002the Key Project of Scientific Research Foundation of Chinese Medicine 2022ZZ002the "Pioneer" and "Leading Goose" R&D Program of Zhejiang 2022C03118the Zhejiang Province Chinese Medicine Modernization Program No.2020ZX001the Zhejiang Provincial Medical and Health Science and Technology Program 2024KY665the Zhejiang Provincial Traditional Chinese Medicine Science and Technology Project 2024ZL287
6 · The paper itself

Abstract

Diabetes nephropathy (DN) is a prevalent and severe microvascular diabetic complication. Despite the recent developments in germacrone-based therapies for DN, the underlying mechanisms of germacrone in DN remain poorly understood. This study used comprehensive bioinformatics analysis to identify critical microRNAs (miRNAs) and the potential underlying pathways related to germacrone activities. Additionally, we established a DN mice model, which was treated with germacrone, to investigate how it altered the miRNA transcriptome in mice kidneys. RNA sequencing was also performed on the DN mice model with and without germacrone pre-treatment. Based on our results, we found 23 miRNAs were differentially expressed in the DN group compared to the controls, and a total of 14 miRNAs were differentially expressed between the DN group and the germacrone-treated group. In addition, we identified three miRNAs (mmu-miR-542-5p, mmu-miR-149-5p and mmu-miR-196a-2-3p) that were upregulated with the DN group and downregulated in the germacrone-treated group. Bioinformatics analysis suggested that autophagy and apoptosis were related to the pathogenesis of DN and germacrone treatment. Subsequently, the expression level of mmu-miR-542-5p, mmu-miR-149-5p and mmu-miR-196a-2-3p were validated in a validation dataset. Altogether, these findings add important knowledge on the pathogenesis of DN and the impacts of germacrone.

Indexed as

Computational BiologyDiabetic NephropathiesMicroRNAsSesquiterpenes, GermacraneAnimalsApoptosisAutophagyDiabetes Mellitus, ExperimentalDisease Models, AnimalGene Expression ProfilingGene Expression RegulationKidneyMaleMiceMice, Inbred C57BLTranscriptomegermacroneMicroRNAsMIRN196 microRNA, mouseSesquiterpenes, Germacrane

Identifiers

PMID39738220
PMCPMC11685625

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.